Navigation Links
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Date:12/5/2011

MALVERN, Pa., Dec. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead Smac mimetic drug candidate, TL32711, in elderly patients with acute myelogenous leukemia (AML). The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

"In preclinical studies on primary human AML samples, TL32711 inhibits the growth and survival of AML cells as demonstrated in colony forming assays and a xenotransplantation model of the disease," said Martin Carroll, M.D., of the Hospital of the University of Pennsylvania. "These encouraging data along with TL32711's novel mechanism of action support its clinical development for AML where new treatment options are needed especially for the elderly."

"This clinical study represents another important step in advancing TL32711 as a potential treatment for AML and supports our goal of providing improved therapies for patients with cancer," said John Gill, TetraLogic's President and Chief Executive Officer.  "The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins (IAPs) represents a new broadly applicable approach to treat cancers that are normally resistant to therapies, including AML."

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological mali
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Having access to safe ... uphill battle in many corners of the globe. It’s ... community in northwestern Bolivia where many have been sickened ... from Fairfield University’s School of Engineering has been working ... Campesina (UAC), “the united college for the peasants.” A ...
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Stronger ... healthcare, construction, finance and consumer electronics will help ... reason, industry research firm IBISWorld has added a ... its growing industry report collection. , The Biometrics ... for biometric technologies such as fingerprint, iris, retina ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Fairfield University School of Engineering project reduces illness in rural community 2Fairfield University School of Engineering project reduces illness in rural community 3Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ), ... Western healthcare products in the People,s,Republic of China, ... fourth quarter which will be reported in the ... filed with the Securities and Exchange Commission,on Monday, ...
... XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today ... and Extraordinary General,Meeting (collectively, the "Meetings") scheduled for July ... at the close of business on,June 12, 2008 are ... Meetings. All,shareholders are cordially invited to attend the Meetings ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY), announced today that ... in two separate presentations at the,BIO 2008 International Convention., ... overview of the,Company on Tuesday, June 17th at 3:30 ... Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson ...
Cached Biology Technology:Chindex International, Inc. Quantifies Fourth Quarter Charges 2Chindex International, Inc. Quantifies Fourth Quarter Charges 3Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting 2Oncolytics Biotech Inc. to Present at BIO 2008 International Convention 2
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... of chemicals from household and industrial products are in ... But for most of them, scientists have yet to ... the first step toward doing that by estimating which ... method is published in the ACS journal Environmental ... colleagues note that the risks to human health of ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... in Proceedings of the National Academy of Sciences, USA, ... the genomics of primitive living fishes such as sharks ... sea squirts. Vertebrates - animals such as ... anatomically and genetically complex of all organisms, but explaining ...
... 11, 2008) Researchers at the Georgia Institute of ... eventually recycle carbon from vehicles to prevent the pollutant ... the atmosphere. Georgia Tech researchers envision a zero emission ... fuels. Technologies to capture carbon dioxide emissions from ...
... Ill. --- In the science world, in the media, ... over how carbon in the atmosphere is affecting global ... Earth is an enormous challenge, but one Northwestern University ... segment -- rivers. Aaron Packman, associate professor of ...
Cached Biology News:Carbon capture strategy could lead to emission-free cars 2Carbon capture strategy could lead to emission-free cars 3Carbon capture strategy could lead to emission-free cars 4Studying rivers for clues to global carbon cycle 2Studying rivers for clues to global carbon cycle 3
Kit containing MACS equipment and reagents for immunopurification of proteins....
... biomarker discovery projects require screening through ... distinguish clinically relevant data from normal ... Manager is now available to help ... and data flood inherent to biomarker ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
Biology Products: